Rocket Pharmaceuticals(US:RCKT) GlobeNewswire News Roomยท2025-06-27 13:42Core Viewpoint - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the safety and clinical trial protocol of its RP-A501 treatment, particularly concerning Serious Adverse Events (SAEs) that occurred during the trial [1][2][4]. Group 1: Allegations and Misrepresentation - The lawsuit claims that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the risks associated with the clinical trial, including the death of participants [2][3]. - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to inflated stock prices based on misleading information [3][4]. Group 2: Impact of the Clinical Hold - On May 27, 2025, Rocket announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient experienced a Serious Adverse Event resulting in death, which was not disclosed to investors prior to the amendment [4]. - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% [5]. Group 3: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP is representing the investors in this case, emphasizing their long-standing expertise in securities litigation and commitment to protecting investor rights [5][6].